SCHEDULE 13G: BlackRock Discloses 10.2% Stake in Kura Oncology, Inc.
Beneficial Ownership Report
BlackRock, Inc. has filed a Schedule 13G, reporting a beneficial ownership of 10.2% of Kura Oncology, Inc.'s common stock as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 7,934,104 shares of Kura Oncology, Inc. common stock.
- This stake represents 10.2% of the total outstanding common shares of Kura Oncology, Inc.
- BlackRock holds sole voting power over 7,698,622 shares and sole dispositive power over 7,934,104 shares.
- The filing is a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- The filing notes that it is an amendment but is being reflected as an initial filing on the EDGAR system due to technical issues.
- BlackRock, Inc. is classified as a parent holding company or control person for the purpose of this filing.
Sentiment
Score: 7
Explanation: The disclosure of a significant passive stake by a major institutional investor like BlackRock is generally viewed positively as it indicates confidence in the company. The technical issue with the filing type is minor and does not detract from the overall positive signal of the investment.
Positives
- A major institutional investor like BlackRock holding a significant stake (10.2%) can signal confidence in Kura Oncology, Inc.'s long-term prospects.
- The filing indicates a passive investment strategy, suggesting BlackRock is not seeking to influence or change control of the company, which can be viewed as a stable, long-term investment.
Future Outlook
NA
Industry Context
This filing reflects a significant passive investment by BlackRock, one of the world's largest asset managers, in Kura Oncology, Inc., a biotechnology company. Such large institutional holdings are common in the biotech sector, where long-term investment in promising drug development companies is a key strategy for many funds. BlackRock's stake suggests a belief in Kura Oncology's potential within the competitive biotechnology landscape.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like BlackRock may instill confidence and potentially influence market perception positively, suggesting a vote of confidence in Kura Oncology, Inc.'s value.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 01/08/2025 | Date of signature for the Schedule 13G filing. |
Keywords
Kura Oncology Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.